Detailed information for compound 434380

Basic information

Technical information
  • TDR Targets ID: 434380
  • Name: (5Z)-5-[[3-(2-hydroxyethoxymethyl)thiophen-2- yl]methylidene]-10-methoxy-2,2,4-trimethyl-1H -chromeno[3,4-f]quinolin-9-ol
  • MW: 491.599 | Formula: C28H29NO5S
  • H donors: 3 H acceptors: 2 LogP: 4.37 Rotable bonds: 6
    Rule of 5 violations (Lipinski): 1
  • SMILES: OCCOCc1ccsc1/C=C/1\Oc2ccc(c(c2c2c1c1C(=CC(Nc1cc2)(C)C)C)OC)O
  • InChi: 1S/C28H29NO5S/c1-16-14-28(2,3)29-19-6-5-18-25(24(16)19)22(13-23-17(9-12-35-23)15-33-11-10-30)34-21-8-7-20(31)27(32-4)26(18)21/h5-9,12-14,29-31H,10-11,15H2,1-4H3/b22-13-
  • InChiKey: CZFMLDUNXATLOW-XKZIYDEJSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (5Z)-5-[[3-(2-hydroxyethoxymethyl)-2-thienyl]methylene]-10-methoxy-2,2,4-trimethyl-1H-chromeno[3,4-f]quinolin-9-ol
  • (5Z)-5-[[3-(2-hydroxyethoxymethyl)-2-thienyl]methylene]-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolin-9-ol

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trypanosoma cruzi Eukaryotic initiation factor 4A-1 0.0126 0.3912 0.5
Plasmodium vivax RNA helicase-1, putative 0.0126 0.3912 0.5
Echinococcus multilocularis eukaryotic initiation factor 4A III 0.0126 0.3912 1
Onchocerca volvulus Eukaryotic initiation factor 4A homolog 0.0126 0.3912 0.5
Echinococcus multilocularis aldehyde dehydrogenase, mitochondrial 0.0064 0.059 0.1509
Schistosoma mansoni aldehyde dehydrogenase 0.0064 0.059 0.1509
Trichomonas vaginalis DEAD box ATP-dependent RNA helicase, putative 0.0126 0.3912 0.5
Leishmania major eukaryotic initiation factor 4a, putative 0.0126 0.3912 1
Entamoeba histolytica DEAD/DEAH box helicase, putative 0.0126 0.3912 0.5
Mycobacterium ulcerans aldehyde dehydrogenase 0.0064 0.059 0.5
Brugia malayi eukaryotic initiation factor 4A 0.0126 0.3912 1
Toxoplasma gondii eukaryotic initiation factor-4A, putative 0.0126 0.3912 1
Echinococcus granulosus eukaryotic initiation factor 4A III 0.0126 0.3912 1
Schistosoma mansoni DEAD box ATP-dependent RNA helicase 0.0126 0.3912 1
Schistosoma mansoni aldehyde dehydrogenase 0.0064 0.059 0.1509
Plasmodium falciparum eukaryotic initiation factor 4A 0.0126 0.3912 0.5
Echinococcus multilocularis eukaryotic initiation factor 4A 0.0126 0.3912 1
Echinococcus granulosus aldehyde dehydrogenase mitochondrial 0.0064 0.059 0.1509
Treponema pallidum ATP-dependent RNA helicase 0.0126 0.3912 0.5
Giardia lamblia Translation initiation factor eIF-4A, putative 0.0126 0.3912 0.5
Trichomonas vaginalis DEAD box ATP-dependent RNA helicase, putative 0.0126 0.3912 0.5
Echinococcus granulosus eukaryotic initiation factor 4A 0.0126 0.3912 1
Trypanosoma cruzi Eukaryotic initiation factor 4A-1 0.0126 0.3912 0.5
Mycobacterium ulcerans aldehyde dehydrogenase 0.0064 0.059 0.5
Leishmania major eukaryotic initiation factor 4a, putative 0.0126 0.3912 1
Trypanosoma brucei Eukaryotic initiation factor 4A-1 0.0126 0.3912 0.5
Schistosoma mansoni DEAD box ATP-dependent RNA helicase 0.0126 0.3912 1
Mycobacterium ulcerans aldehyde dehydrogenase 0.0064 0.059 0.5
Loa Loa (eye worm) hypothetical protein 0.0126 0.3912 1
Mycobacterium tuberculosis Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) 0.0126 0.3912 0.353
Trichomonas vaginalis DEAD box ATP-dependent RNA helicase, putative 0.0126 0.3912 0.5

Activities

Activity type Activity value Assay description Source Reference
EC50 (functional) = 1.6 nM Agonist activity at human GR expressed in CV1 cells by GRE activation assay ChEMBL. 17705362
EC50 (functional) = 1.6 nM Agonist activity at human GR expressed in CV1 cells by GRE activation assay ChEMBL. 17705362
Efficacy (functional) = 58 % Agonist efficacy at human GR expressed in CV1 cells by GRE activation assay relative to dexamethasone ChEMBL. 17705362
Efficacy (functional) = 58 % Agonist efficacy at human GR expressed in CV1 cells by GRE activation assay relative to dexamethasone ChEMBL. 17705362
Efficacy (binding) = 98 % Absolute efficacy at human GR expressed in NHDFneo cells assessed as repression of IL-6 production relative to dexamethasone ChEMBL. 17705362
Efficacy (functional) = 98 % Antiproliferative activity against human RPMI8226 cells after 4 days relative to dexamethasone ChEMBL. 17705362
Efficacy (binding) = 98 % Absolute efficacy at human GR expressed in NHDFneo cells assessed as repression of IL-6 production relative to dexamethasone ChEMBL. 17705362
Efficacy (functional) = 98 % Antiproliferative activity against human RPMI8226 cells after 4 days relative to dexamethasone ChEMBL. 17705362
IC50 (binding) = 1 nM Activity at human GR expressed in NHDFneo cells assessed as inhibition of IL-6 production ChEMBL. 17705362
IC50 (binding) = 1 nM Activity at human GR expressed in NHDFneo cells assessed as inhibition of IL-6 production ChEMBL. 17705362
IC50 (functional) = 22 nM Antiproliferative activity against human RPMI8226 cells after 4 days ChEMBL. 17705362
IC50 (functional) = 22 nM Antiproliferative activity against human RPMI8226 cells after 4 days ChEMBL. 17705362

Phenotypes

Whole-cell/tissue/organism interactions

Species name Source Reference Is orphan
Homo sapiens ChEMBL23 17705362

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.